Atherosclerosis Wire
Comprehensive News Feed for Atherosclerosis.
Results 1 - 20 of 85 in Atherosclerosis
-
Arena says Merck ending work on atherosclerosis drug
Arena Pharmaceuticals Inc. said Merck & Co . ended work on an experimental drug for atherosclerosis, or clogged arteries, that the two companies were developing in collaboration. Comment?
-
Bristol-Myers Reduces 2009 Outlook
... cancer. Plavix, the antiplatelet blood thinner indicated for reducing heart attack risks in patients with atherosclerosis, is the top growth driver at Bristol. However, patent expirations loom large on the company starting 2011, when Plavix is ... Comment?
-
Arena Pharmaceuticals, Merrimac, Omnicare: U.S. Equity Preview
... US) has decided to discontinue development of MK-1903, an investigational niacin receptor agonist to treat atherosclerosis being developed under its research collaboration with Arena. Merrimac Industries Inc. (MRM US) surged 38 percent to $15.92. ... Comment?
-
International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential
... relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998;32:1648-56. [3] Farnier M, Freeman MW, Macdonell G, Perevozskaya I, ... Comment?
-
International, Well-Known Scientific Experts Say That New GFT505 Data ...
... relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998;32:1648-56. [3] Farnier M, Freeman MW, Macdonell G, Perevozskaya I, ... Comment?
-
Analysis of Drug Eluting Stent Coating Solutions Using FT-NIR Spectroscopy
A drug-eluting stent is an expandable metal alloy framework placed into narrowed coronary arteries that slowly releases a drug coating to treat atherosclerosis. Comment?
-
Bristol Amends & Extends Offer
... cancer. Plavix, the antiplatelet blood thinner indicated to reduce the risk of heart attack in patients with atherosclerosis, is the top growth driver for Bristol. However, patent expirations loom large on the company starting 2011 when Plavix is ... Comment?
-
Stroke And Heart Disease Trigger Revealed In New Research
Scientists have identified the trigger that leads to the arteries becoming damaged in the disease atherosclerosis, which causes heart attacks and strokes, in research published today in the journal Circulation. Comment?
-
Stroke And Heart Disease Trigger Revealed In New Research
Main Category: Stroke Also Included In: Cardiovascular / Cardiology ; Vascular ; Infectious Diseases / Bacteria / Viruses Article Date: 01 Dec 2009 - 6:00 PST Scientists have identified the trigger that leads to the arteries becoming damaged in the disease atherosclerosis, which causes heart attacks and strokes , in research published recently in ... Comment?
-
Stroke and heart disease trigger revealed
- Scientists have identified the trigger that leads to the arteries becoming damaged in the disease atherosclerosis, which causes heart attacks and strokes, in research published in the journal Circulation . The authors of the study, from Imperial ... Comment?
-
Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study
... plaque, a thick, hard deposit that narrows arteries and makes them less flexible. This condition is known as atherosclerosis. HDL, on the other hand, protects the blood vessels by carrying cholesterol away from the arteries and back to the liver, ... Comment?
-
Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CAD
... imaging study from Johns Hopkins experts shows. In tests on 145 Baltimore-area men and women with existing atherosclerosis, all over age 65, researchers found that after 18 months of drug therapy, reductions in arterial wall thickness were ... Comment?
-
Vitamin B Niacin Offers No Additional Benefit To Statin Therapy In...
... imaging study from Johns Hopkins experts shows. In tests on 145 Baltimore-area men and women with existing atherosclerosis, all over age 65, researchers found that after 18 months of drug therapy, reductions in arterial wall thickness were ... Comment?
-
Queen's iGEM team wins bronze in international competition
... systems synthetically from the ground up. QGEM explored a new synthetic biology approach for treating atherosclerosis, a disease in which plaque builds up inside the arteries. They aimed to engineer bacteria that could target and deliver drugs to ... Comment?
-
Don't stop taking your Zetia yet
... , which is Zetia plus simvastatin, is no more effective than simvastatin alone in reducing the amount of atherosclerosis in the carotid (neck) arteries of the research subjects. The participants in the ENHANCE study, however, have a genetic form of ... Comment?
-
Even The Pharaohs Needed Lipitor
w/Photo
... visiting a museum in Cairo when he read that Pharaoh Merenptah, who lived around 1200 BC, suffered from atherosclerosis. "I didn't believe it," he says. But he realized it could be useful to know if the disease is something humans had long suffered ... Comment?
-
Merck's Investigational Anacetrapib Phase IIb Study Results Presented ...
... (LDL-C) in exchange for triglycerides. Low levels of HDL-C are associated with an increased risk of atherosclerosis (the formation of plaques in arteries) and coronary heart disease (CHD). Research has shown that inhibition of CETP is associated ... Comment?
-
NicOx - NCX 6560 meets primary and secondary objectives in first-in-man study
... in the key processes underlying the most common cardiovascular disorders, such as endothelium dysfunction, atherosclerosis and thrombosis. NCX 6560 is a New Chemical Entity (NCE) that is an NO-donating atorvastatin, which is designed to provide ... Comment?
-
New Data: Cholesterol Management Analysis of Upsher-Smith's...
... plaque, a thick, hard deposit that narrows arteries and makes them less flexible. This condition is known as atherosclerosis. HDL, on the other hand, protects the blood vessels by carrying cholesterol away from the arteries and back to the liver, ... Comment?
-
... the ARBITER 6 - HALTS study showed that patients at high cardiovascular risk showed significant reduction in atherosclerosis after 8 and 14 months of therapy with Abbott's Niaspan plus a statin, the study's primary endpoint. The study met its ... Comment?
Atherosclerosis Forum
Most Popular
- A bleak future for black children and youth - 482 comments
- Glenn Beck Named "Misinformer Of The Year" - 482 comments
- Angels can't fly, scientist says - 184 comments
- 911? My son won't stop playing video games - 85 comments
- The Europe Union is discriminating Muslims - 232 comments
- Father forces suspected gay son to have sex with hooker. - 59 comments
- End of the Decade: Bush Era, Shadow of 9/11 - 62 comments
- Thousands in E. Ky. still without power, water in freezing temps - 60 comments
- Police search for supermarket butt sniffer - 55 comments
- Merry Christmas: Obamacare Slaps $15,000 Annual Fee on Middle Class Families - 62 comments
|
Reach local customers. Engage a specific demographic. Maximize business-to-business opportunities. Topix can deliver your message.
|
Copyright ©2009 Topix LLC
